Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis

Dongyang Li; Hang Lv; Xuanyu Hao; Yudi Dong; Huixu Dai; Yongsheng Song

doi:10.18632/oncotarget.19680

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis

Dongyang Li, Hang Lv, Xuanyu Hao, Yudi Dong, Huixu Dai and Yongsheng Song _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:84449-84458. https://doi.org/10.18632/oncotarget.19680

Metrics: PDF 1469 views | HTML 2320 views | ?

Abstract

Dongyang Li1,*, Hang Lv2,*, Xuanyu Hao3, Yudi Dong4, Huixu Dai5 and Yongsheng Song1

1Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China

2Department of Urology, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, Liaoning 110042, P.R. China

3Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110022, P.R. China

4Department of Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China

5Department of Clinical Epidemiology and Evidence-based Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China

*These authors contributed equally to this work

Correspondence to:

Yongsheng Song, email: [email protected]

Keywords: metastatic prostate cancer, bone scan index, prognosis, survival, meta-analysis

Received: March 26, 2017 Accepted: June 30, 2017 Published: July 29, 2017

ABSTRACT

Background: The prognostic value of the bone scan index (BSI) in metastatic prostate cancer (mPCa) remained controversial. Therefore, we performed a meta-analysis to determine the predictive value of BSI and survival in patients with mPCa.

Materials and Methods: A literature search was performed in PubMed, Embase, Web of Science and Cochrane library databases. Hazard ratios (HRs), concordance indices (C-indices) were extracted to estimate the relationship between BSI and survival in patients with mPCa. Subgroup analyses were conducted on different types of mPCa, ethnics, cut-off values and sample sizes.

Results: 14 high quality studies involving 1295 patients with mPCa were included in this meta-analysis. The pooled results indicated that high basline BSI and elevated BSI change on treatment (ΔBSI) were significantly predictive of poor overall survial (HR = 1.29, P < 0.001; HR = 1.27, P < 0.001, respectively). Baseline BSI was also significantly related to cancer specific survival (HR = 1.65, P = 0.019) and prostate specific antigen recurrence survival (HR = 2.26, P < 0.001). Subgroup analysis supported main results. Moreover, BSI could increase the C-indices of predictive models.

Conclusions: Baseline BSI and ΔBSI may be beneficial to mPCa prognosis in clinical monitor and treatment. Further high quality studies with larger sample size are required in the future.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19680

Publication Alerts

Meta-Analysis:

Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis

Abstract